Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2019 2
2020 2
2021 2
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean kotov k[au] (147 results)?
Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer.
Gorodnova TV, Kotiv KB, Ivantsov AO, Mikheyeva ON, Mikhailiuk GI, Lisyanskaya AS, Mikaya NA, Guseynov KD, Bondarev NE, Matveyeva NS, Nekrasova EA, Sidoruk AA, Roman LD, Manikhas GM, Belyaev AM, Sokolenko AP, Berlev IV, Imyanitov EN. Gorodnova TV, et al. Among authors: kotiv kb. Int J Gynecol Cancer. 2018 Oct;28(8):1498-1506. doi: 10.1097/IGC.0000000000001352. Int J Gynecol Cancer. 2018. PMID: 30247247
Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients.
Sokolenko AP, Gorodnova TV, Bizin IV, Kuligina ES, Kotiv KB, Romanko AA, Ermachenkova TI, Ivantsov AO, Preobrazhenskaya EV, Sokolova TN, Broyde RV, Imyanitov EN. Sokolenko AP, et al. Among authors: kotiv kb. Cancer Chemother Pharmacol. 2021 Sep;88(3):439-450. doi: 10.1007/s00280-021-04301-6. Epub 2021 Jun 2. Cancer Chemother Pharmacol. 2021. PMID: 34080040
Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers.
Sokolenko AP, Savonevich EL, Ivantsov AO, Raskin GA, Kuligina ES, Gorodnova TV, Preobrazhenskaya EV, Kleshchov MA, Tiurin VI, Mukhina MS, Kotiv KB, Shulga AV, Kuznetsov SG, Berlev IV, Imyanitov EN. Sokolenko AP, et al. Among authors: kotiv kb. Cancer Lett. 2017 Jul 1;397:127-132. doi: 10.1016/j.canlet.2017.03.036. Epub 2017 Apr 1. Cancer Lett. 2017. PMID: 28377179